CD19 and diffuse large B-cell lymphoma: In this study, we reported the institutional experience at the First Affiliated Hospital of Soochow University from 33 decitabine-containing lymphodepletion regimens pretreated and tandem CD19/CD22 CAR-T infused R/R DLBCL patients drawn out from one ongoing phase II trial testing efficacy and toxicities of CAR-T therapy in R/R Non-Hodgkin lymphoma patients (http://ClinicalTrials.gov NCT03196830).